industry enterprises in the China Pharmaceutical Statistics Annual Report 2019. Relying on IMM of production-academy-research mechanism for new drugs with Chinese characteristics, the two factories have successfully translated a series of innovative drugs and generic drugs for the treatment of major diseases. As a high-tech enterprise and Beijing Intellectual Property Demonstration Unit, Enterprise Technology Center, Science and Technology R&D Institution and "Specialized, Special New" Little Giant Enterprise, the two factories have increased investment in R&D, and have undertaken a number of scientific and technological projects such as the National Major New Drug Innovation Project. The company has obtained nearly 20 in total of new drug certificates, production approvals and clinical approvals. Numerous new drugs and modified drugs are at study, in pre-clinical studies or in different stages of clinical studies. Nearly 50 in total of invention patents have been authorized at home and abroad.
The two factories respond actively to the appeal of Collaborative Development of Beijing, Tianjin and Hebei Province. Located in Bio–medicine Industry Park, Daxing District, the Beijing production base covers 46,000 square meters and it is recognized as Green Factory by Ministry of Industry and Information Technology. The Beijing base owns production lines for tablets, capsules, drop pills, creams and ointments, freeze-dried powder injections (antineoplastic agents) and small volume injections (including antineoplastic agents). Bicyclol Tablets received GMP certificate from Ukraine, a member of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). The Cangzhou production base of BUPF, located in the Biomedical Industrial Park of Bohai New District, Cangzhou –Beijing has started production of bicyclol APIs at the end of 2019.
Representative products of the two factories include: anti-hepatitis drug-Bicyclol Tablets (Bicyclol®), Bifendate Pills, anti-hypertension drug-Felodipine Tablets, antineoplastic agent-Paclitaxel Injection, Epirubicin Hydrochloride Injection, and key raw material of Artificial Musk. The first class chemical drug-bicyclol, won the second prize of the National Science and Technology Progress Award and the first prize of the Beijing Science and Technology Award. It was selected as one of the top ten scientific and technological achievements in the 60th anniversary of the founding of the Chinese Academy of Medical Sciences. Bicyclol was listed in the National Basic Medical Insurance, Work Injury Insurance, 31 domestic and foreign guidelines including Guidelines for Prevention and Treatment of Chronic Hepatitis B, and 8 clinical pathways including drug-induced liver injury. It has been registered and marketed in many countries along the "Belt and Road" such as Russia, Ukraine, Kyrgyzstan, etc., creating significant social and economic benefits.
